Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative inflammation and immunology (“I&I”) biological products, is announcing the publication of a peer-reviewed article regarding NanoAbs. The article reports on data that supports the use of Scinai’s aerosolized NanoAbs as a platform for the treatment of hyperinflammatory viral diseases, which addresses significant medical needs. Titled “Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters,” the article is published in the prominent “Antiviral Research” journal. According to the announcement, the article focused on a new generation of anti-SARS-CoV-2 NanoAbs, identified as nanobodies or VHH (“VHH”) antibodies. These antibodies were developed as the result of a research collaboration between the Max Planck Institute for Multidisciplinary Sciences (“MPI-NAT”), the University Medical Center Göttingen (“UMG”) and Scinai Immunotherapeutics. The antibodies, which are alpaca–derived recombinant variable domain of heavy-chain-only antibodies, are exclusively licensed to Scinai. Scinai chief scientist Dr. Tamar Ben-Yididia coauthored the paper with Professor Dirk Görlich, MPI-NAT director, and UMG Professor Matthias Dobbelstein, along with others.
“These results are a striking proof-of-concept for the use of inhaled NanoAbs for the treatment of hyperinflammatory respiratory viral diseases,” said Scinai chief scientist Dr. Tamar Ben-Yididia in the press release. “We are proud that our first NanoAb development project has been published in the prestigious peer-reviewed scientific journal ‘Antiviral Research,’ as it validates our R&D strategy by clearly demonstrating our NanoAbs’ potential superiority to existing therapies in several ways, including innate stability leading to more convenient routes of administration such as inhalation. While COVID-19 has dropped from the headlines, it continues to circulate and cause illness. We strongly believe that convenient self-administered treatments and prophylactics form the future of respiratory viral-disease pharmaceuticals, and the data in this paper demonstrates the exciting potential of our NanoAbs to fill this vital role. Indeed, we are currently actively marketing this COVID-19 project for partnering with either pharma companies or governmental health agencies. Our next pipeline project is an anti-IL-17 NanoAb for the treatment of autoimmune diseases such as plaque psoriasis and psoriasis arthritis. Recent preclinical results have been promising, and I look forward to sharing more results soon.”
To view the article, visit https://ibn.fm/fKgtl
To view the full press release, visit https://ibn.fm/0EqAf
About Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics is a biopharmaceutical company with two complementary business units: one focused on in-house development of inflammation and immunology (“I&I”) biological products beginning with an innovative, derisked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO (“CDMO”) providing services to help biotech companies efficiently bring their products to market by leveraging Scinai’s drug development and GMP and non-GMP manufacturing capabilities for preclinical and clinical studies. For more information, visit the company’s website at www.Scinai.com.
NOTE TO INVESTORS: The latest news and updates relating to SCNI are available in the company’s newsroom at https://ibn.fm/SCNI
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed)and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN